CAR T cell Therapy Market

CAR T cell Therapy Market Size (2023 to 2028)

The global CAR T cell therapy market is growing continuously due to innovation and development in this therapy. As a result, the Global CAR T cell therapy market is expected to be worth USD 4.36 billion by 2028 from 2.31 billion in 2023, growing with a healthy CAGR of 13.5% during the forecast period.

CAR T cell Therapy Market Share insights:

• Based on target antigen, CD/19 & CD/22 segments captured a major share of the global CAR T cell therapy market in 2022.
• Based on the application, the multiple myeloma segment held the largest share of the global market in 2022.
• Based on the product, the autologous segment occupied the leading share of the global market in 2022.
• The North American region accounted for the largest global market share in 2021.
• The Europe CAR T cell market captured a substantial share of the worldwide market in 2021 and is expected to grow at a CAGR of 15.56% during the forecast period.

CAR T cell therapy is one of the effective treatment options for cancer. CAR T cell therapy is an immunotherapy in which a patient’s T cells are collected and genetically modified to make them capable of attacking and killing cancer cells. The genetically engineered T cells would be infused into the patient’s body to fight the cancer cells. The demand for these therapies is growing significantly due to the benefits of CAR T cell therapies among healthcare providers and patients. On the other side, the adoption and access to CAR T cell therapies are limited due to the high costs associated and unavailability.

MARKET DRIVERS:

The growing cancer patient population is one of the major factors propelling the CAR T cell therapy market growth.

The number of people who have cancer is growing significantly worldwide with each year passing. Cancer caused one in every six deaths in 2020, said WHO. As per the data published by the Centers for Disease Prevention and Control (CDC), an estimated 1,752,735 new cancer cases and 599,589 cancer deaths were recorded in 2019. CAR T cell therapy has gained popularity as one of the effective treatment options to fight against cancer. It has a history of promising results in treating leukemia and lymphoma cancers. Due to this, the adoption of CAR T cell therapies is growing and driving the market growth. To date, the USFDA approved six CAR T cell therapies.

The growing number of initiatives and funding from various governments in favor of CAR T cell therapies is further anticipated to boost the market’s growth rate.

The governments of several countries have taken numerous initiatives to promote awareness regarding CAR T cell therapies among people and funded to conduct of R&D around CAR T cell therapies. For instance, the National Cancer Institute (NCI) invested hefty amounts in the research and development of CAR T cell therapies and established several research centers. In addition, the governments of some countries have extended their support for CAR T cell therapies by providing regulatory support, favorable reimbursement policies, partnering with private companies, and conducting clinical trials. Such initiatives and investments from the governments are anticipated to boost the growth of the CAR T cell therapy market.

The rising investments by the major market participants are estimated to fuel the growth rate of the CAR T cell therapy market.

The key market players such as Novartis and Kite Pharma, have announced that they spend huge amounts on the R&D of CAR T cell therapies to develop new therapies and improve their effectiveness.

In addition, the rising number of advancements in the biotechnology industry and growing awareness among healthcare providers and patients regarding the benefits of CAR T cell therapy are boosting the market’s growth rate.  Furthermore, implementing advanced technologies and innovative treatment procedures with fewer side effects is expected to surge the market's growth rate. Furthermore, the growing investments in research institutes related to cell therapy are another considerable factor supporting CAR T cell cancer therapy market growth.

MARKET RESTRAINTS:

High costs associated with CAR T cell therapies are one of the major factors hampering the market growth. CAR T cell therapy costs a bit expensive, which cannot be affordable by ordinary people. In addition, the lack of awareness in rural areas regarding the therapeutic process for cancer disease slightly restrains the CAR T cell therapy market's growth rate.  Furthermore, an increasing adverse drug reaction concern with cell therapy in Cytokine syndrome problems and neurological problems is expected to hamper the CAR T cell therapy market growth.

Impact of COVID-19 on the CAR-T cell therapy Market:

The COVID-19 pandemic has had a significant impact on the growth of the CAR T cell therapy market. Due to the COVID-19 pandemic, the clinical trials of CAR T cell therapies have been delayed as hospitals and research centers prioritized the needs of COVID-19 patients, which resulted in the delay in conducting clinical trials for CAR T cell therapies. In addition, the COVID-19 pandemic has also resulted in the disruption of the supply chain. Due to this, it became complicated for the market participants to source materials required to conduct R&D of CAR T cell therapies. In addition, the COVID-19 pandemic has restricted access to CAR T cell therapies to patients in need, as all the non-essential medical procedures were kept on hold. Such factors resulted negatively in the growth of the CAR T cell therapy market.

Conversely, some patients have had CAR T cell therapy by telemedicine and virtual consultations. In addition, the governments of some countries have increased their investments in the R&D of CAR T cell therapies during the COVID-19 pandemic. These factors favored the growth of the CAR T cell therapy market slightly. However, considering the decreasing impact of the COVID-19 pandemic and growing habituation towards the new normalization by people and research centers, the CAR T cell therapy market is estimated to register a healthy CAGR during the forecast period.

REPORT COVERAGE:

This research report on the global CAR T Cell therapy market is segmented and sub-segmented based on target antigen, Application, Product, therapies, and Region.

CAR T cell Therapy Market - By Target Antigen:

• CD20
• EGFRV III
• CD19
• HER2
• MESO
• CD22
• BCMA
• GD2
• CD30
• HER1
• CD33

Based on target antigen, CD19, and CD22 accounted for the largest share of the global CAR T cell therapy market in 2022 and are expected to continue their dominance throughout the forecast period. Recently, several companies got their antigens approved. As a result, it also increases the CAR T-cell therapy market.

However, B-cell maturation antigens are anticipated to fastest growth due to their distinctive antigens such as MUC16, ROR1, and L1CAM.

CAR T cell Therapy Market - By Application:

• Multiple Myeloma
• Chronic Lymphocytic Leukemia
• Mantle Cell Lymphoma
• Follicular Lymphoma
• Diffuse large B-cell lymphoma
• Acute Lymphoblastic Leukemia

Based on the application, the multiple myeloma segment captured the major share of the global CAR T cell therapy market in 2022 and is anticipated to continue its domination throughout the forecast period.

The chronic lymphocytic leukemia segment is expected to grow at a notable CAGR during the forecast period.

The Diffuse large B-cell lymphoma (DLBCL) segment is another lucrative segment and is forecasted to hold a considerable share of the worldwide market during the forecast period.

CAR T cell Therapy Market - By Product:

• Allogeneic
• Autologous

Based on the product, the autologous segment is anticipated to lead the CAR T Cell therapy market during the forecast period owing to the several potential competitors.

CAR T cell Therapy Market Analysis - By Therapies:

• Axicabtagene ciloleucel (Yescarta)
• Tisagenlecleucel (Kymriah)

Based on therapies, the axicabtagene ciloleucel (Yescarta) segment is expected to have a notable share of the global CAR T cell therapy market during the forecast period owing to the developing healthcare infrastructure and growing discretionary expenses.

CAR T cell Therapy Market – By End User:

• Cancer Research Centers
• Hospitals
• Academic and Research Institutes
• Pharmaceutical Companies
• Biotechnology Companies
• Contract Research Organizations

Based on the end-user, the biotechnology and pharmaceutical companies segment had a major share of the CAR T cell therapy market worldwide in 2022. The segment’s domination is expected to continue during the forecast period owing to the advanced research being carried out at the companies.

CAR T cell Therapy Market Analysis – By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• The Middle East and Africa

Geographically, the North American CAR T cell Therapy market occupied the most significant share of the global market in 2021, and the region’s domination is expected to continue throughout the forecast period. The region's growth is primarily attributed to factors such as rapid adoption of technological developments, increasing cancer patient population, and growing demand for CAR T cell therapies. In addition, the North American market is estimated to experience significant growth during the forecast period due to academic institutions, government authorities, and several manufacturing industries. The U.S. occupied the major North American market, followed by Canada in 2021. The U.S. market growth is primarily driven by the rapid development and launch of innovative therapies by major market participants to treat Cancer and the large patient pool suffering from cancer.

The European CAR T cell Therapy market is another promising regional market for CAR T cell therapies worldwide. It is expected to hold a substantial global market share during the forecast period. The growth of the European region is anticipated to be boosted by the growing number of approvals for CAR T cell therapies. For instance, the European Medicine Agency recently approved two CAR T cell therapies, Kymriah and Yescarta. Factors such as growing R&D activities, increasing regulatory approvals for new CAR T cell therapies, and the increasing number of cancer awareness programs across the European region are further anticipated to fuel the growth rate of the European market. Swedish Cancer Institute is pleased to give qualifying patients Chimeric Antigen Receptor (CAR)-T cell therapy, one of the most recent immunotherapy types that have resulted in widespread patient remission since its approval in 2017. However, since CAR-T cell therapy was only recently approved in April 2017, insurance companies still plan policies for FDA-approved therapies, including CAR-T cell therapy.

During the forecast period, the APAC CAR T cell Therapy market is estimated to grow rapidly and showcase the fastest CAGR among all the regions worldwide. The growing research and developmental activities and the presence of emerging economies majorly drive the growth of the APAC market. As a result, India, Japan, and China are anticipated to hold a major share of the APAC market in the coming years.

During the forecast period, the Latin American market is predicted to hold a considerable share of the worldwide market.

The MEA market is expected to grow at a moderate CAGR in the coming years.

KEY MARKET PARTICIPANTS:

Companies playing a leading role in the global CAR T cell therapy market profiled in this report are Mustang Bio, Inc., Celgene Corporation, Bluebird Bio, Inc., CARsgen Therapeutics, Ltd., Novartis International AG, Legend Biotech, Sorrento Therapeutics Inc., Kite Pharma, Inc., Immune Therapeutics, Bellicum Pharmaceuticals, Inc. and Pfizer, Inc.

RECENT MARKET DEVELOPMENTS:

• In Dec 2019, the Swiss government approved the insurance coverage for CAR T cell therapies from Gilead Sciences' Yescarta and Novartis's Kymriah. This initiative from the Swiss Government significantly reduces the financial burden on cancer patients seeking CAR T cell therapies. In addition, it provides access to CAR T cell therapies to blood cancer patients in need.  
• In April 2018, Pfizer partnered with Allogene to enhance growth and business in allogeneic CAR T cell therapies.
• In 2018, the Ziopharm Company partnered with Intrexon to advance and develop CAR T cell cancer therapy treatment for substantial tumor disease.